172 related articles for article (PubMed ID: 38155965)
1. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
3. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
4. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract][Full Text] [Related]
5. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
9. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
10. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
Xiaoxu D; Min X; Chengcheng C
BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
[TBL] [Abstract][Full Text] [Related]
11. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
13. Combination of Tertiary Lymphoid Structure and Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients With Hepatocellular Carcinoma.
Wen S; Chen Y; Hu C; Du X; Xia J; Wang X; Zhu W; Wang Q; Zhu M; Chen Y; Shen B
Front Immunol; 2021; 12():788640. PubMed ID: 35095864
[TBL] [Abstract][Full Text] [Related]
14. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
16. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
Yan X; Li G
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
Fukuhara M; Muto S; Inomata S; Yamaguchi H; Mine H; Takagi H; Ozaki Y; Watanabe M; Inoue T; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Cancer Immunol Immunother; 2022 May; 71(5):1129-1137. PubMed ID: 34596720
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.
Hou Z; Zhao L; Zou L; Li B
Adv Clin Exp Med; 2023 Aug; 32(8):847-853. PubMed ID: 36881364
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a prognostic nomogram combining PET/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy].
Kong D; Song L; Xiang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Dec; 43(12):2139-2144. PubMed ID: 38189402
[TBL] [Abstract][Full Text] [Related]
20. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]